Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 688

X
Drug Profile

E 688

Alternative Names: B7H3 x Sialidase - Palleon Pharmaceuticals; E-688

Latest Information Update: 28 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palleon Pharmaceuticals
  • Class Antineoplastics; Enzymes; Fab fragments; Immunoconjugates; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Neuraminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Jan 2025 Preclinical trials in Cancer in USA (Parenteral) prior to January 2025 (Palleon Pharmaceuticals pipeline, January 2025)
  • 14 Oct 2022 Palleon Pharmaceuticals has patent protection for use of antibody sialidase conjugates in USA
  • 28 Jun 2022 E 688 licensed to Henlius Biopharmaceuticals in China, Hong Kong, Macau, and Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top